BG107139A - Инхибитор тип 1 (nнe-1) обменящ натрий - водород - Google Patents

Инхибитор тип 1 (nнe-1) обменящ натрий - водород Download PDF

Info

Publication number
BG107139A
BG107139A BG107139A BG10713902A BG107139A BG 107139 A BG107139 A BG 107139A BG 107139 A BG107139 A BG 107139A BG 10713902 A BG10713902 A BG 10713902A BG 107139 A BG107139 A BG 107139A
Authority
BG
Bulgaria
Prior art keywords
compound
tissue
prodrug
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BG107139A
Other languages
Bulgarian (bg)
English (en)
Inventor
Weichao Chen
Eric COX
- PEREZ Angel GUZMAN
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG107139A publication Critical patent/BG107139A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preventing Corrosion Or Incrustation Of Metals (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG107139A 2000-04-28 2002-09-23 Инхибитор тип 1 (nнe-1) обменящ натрий - водород BG107139A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20043200P 2000-04-28 2000-04-28
PCT/IB2001/000277 WO2001083470A1 (en) 2000-04-28 2001-02-28 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

Publications (1)

Publication Number Publication Date
BG107139A true BG107139A (bg) 2003-07-31

Family

ID=22741697

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107139A BG107139A (bg) 2000-04-28 2002-09-23 Инхибитор тип 1 (nнe-1) обменящ натрий - водород

Country Status (40)

Country Link
EP (1) EP1276737A1 (es)
JP (1) JP2003531900A (es)
KR (1) KR20020093079A (es)
CN (1) CN1225466C (es)
AP (1) AP2002002651A0 (es)
AR (1) AR028375A1 (es)
AU (1) AU2001235896A1 (es)
BG (1) BG107139A (es)
BR (1) BR0110268A (es)
CA (1) CA2407535A1 (es)
CO (1) CO5221125A1 (es)
CR (1) CR6797A (es)
CZ (1) CZ20023408A3 (es)
DZ (1) DZ3310A1 (es)
EA (1) EA004882B1 (es)
EE (1) EE200200615A (es)
GT (1) GT200100064A (es)
HN (1) HN2001000042A (es)
HR (1) HRP20020851A2 (es)
HU (1) HUP0300651A2 (es)
IL (1) IL152075A0 (es)
IS (2) IS6567A (es)
MA (1) MA26897A1 (es)
MX (1) MXPA02010600A (es)
MY (1) MY133842A (es)
NO (1) NO20025132L (es)
NZ (1) NZ521348A (es)
OA (1) OA12256A (es)
PA (1) PA8513301A1 (es)
PE (1) PE20011270A1 (es)
PL (1) PL357765A1 (es)
SK (1) SK14872002A3 (es)
SV (1) SV2002000418A (es)
TN (1) TNSN01065A1 (es)
TR (1) TR200202439T2 (es)
UA (1) UA73348C2 (es)
UY (1) UY26680A1 (es)
WO (1) WO2001083470A1 (es)
YU (1) YU79602A (es)
ZA (1) ZA200208605B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518686A (ja) * 2001-01-31 2004-06-24 ファイザー・プロダクツ・インク ナトリウム−水素交換輸送体1型阻害剤のエタノラート
EP1456181A1 (en) * 2001-12-19 2004-09-15 Pfizer Products Inc. Methods for preparing sodium-hydrogen exchanger type-1 inhibitors
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
ES2220185B1 (es) * 2002-07-16 2006-04-01 Consejo Sup. De Investig. Cientificas Nuevo peptido inhibidor del intercambiador na+/h+ (pinhe), y sus aplicaciones.
MXPA05008612A (es) * 2003-02-14 2005-12-05 Smithkline Beecham Corp Compuestos novedosos.
RU2518741C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ГАЛОГЕНИДЫ 1-ДИАЛКИЛАМИНОЭТИЛ-3-[ЗАМЕЩЕННЫЙ(ДИЗАМЕЩЕННЫЙ) ФЕНАЦИЛ]-2-АМИНОБЕНЗИМИДАЗОЛИЯ

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
EE200200615A (et) 2004-04-15
WO2001083470A1 (en) 2001-11-08
UA73348C2 (en) 2005-07-15
HN2001000042A (es) 2001-07-09
HUP0300651A2 (hu) 2003-07-28
HRP20020851A2 (en) 2005-02-28
JP2003531900A (ja) 2003-10-28
IL152075A0 (en) 2003-05-29
UY26680A1 (es) 2001-12-28
TR200202439T2 (tr) 2003-02-21
SV2002000418A (es) 2002-07-03
SK14872002A3 (sk) 2004-03-02
AR028375A1 (es) 2003-05-07
CN1225466C (zh) 2005-11-02
OA12256A (en) 2003-11-06
CA2407535A1 (en) 2001-11-08
MA26897A1 (fr) 2004-12-20
PA8513301A1 (es) 2003-09-05
EA200201023A1 (ru) 2003-02-27
CO5221125A1 (es) 2002-11-28
PE20011270A1 (es) 2001-12-12
GT200100064A (es) 2002-03-22
CR6797A (es) 2004-05-17
NO20025132D0 (no) 2002-10-25
AU2001235896A1 (en) 2001-11-12
IS6567A (is) 2002-09-24
EP1276737A1 (en) 2003-01-22
EA004882B1 (ru) 2004-08-26
PL357765A1 (en) 2004-07-26
KR20020093079A (ko) 2002-12-12
ZA200208605B (en) 2003-10-24
MXPA02010600A (es) 2003-03-10
YU79602A (en) 2006-05-25
DZ3310A1 (fr) 2001-11-07
IS6588A (is) 2002-10-21
AP2002002651A0 (en) 2002-12-31
CZ20023408A3 (cs) 2004-01-14
NO20025132L (no) 2002-12-12
NZ521348A (en) 2004-09-24
BR0110268A (pt) 2003-12-30
TNSN01065A1 (fr) 2005-11-10
MY133842A (en) 2007-11-30
CN1426404A (zh) 2003-06-25

Similar Documents

Publication Publication Date Title
RU2208607C2 (ru) Сульфонамидсодержащие соединения индола
BG107139A (bg) Инхибитор тип 1 (nнe-1) обменящ натрий - водород
KR100464526B1 (ko) 나트륨-수소 교환체 타입 1 억제제 결정
US6852733B2 (en) Sodium-hydrogen exchanger type 1 inhibitor
RU2190605C2 (ru) Способ получения мономезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина
KR20200102565A (ko) 피라졸로피리다진 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
AU2005201428A1 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor